Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells.

Morandi F, Marimpietri D, Horenstein AL, Corrias MV, Malavasi F.

Oncoimmunology. 2019 Feb 19;8(5):e1574198. doi: 10.1080/2162402X.2019.1574198. eCollection 2019.

2.

Plasma free metanephrines for diagnosis of neuroblastoma patients.

Barco S, Verly I, Corrias MV, Sorrentino S, Conte M, Tripodi G, Tytgat G, van Kuilenburg A, van der Ham M, de Sain-van der Velden M, Garaventa A, Cangemi G.

Clin Biochem. 2019 Apr;66:57-62. doi: 10.1016/j.clinbiochem.2019.02.012. Epub 2019 Feb 26.

PMID:
30822416
3.

HIF-1 transcription activity: HIF1A driven response in normoxia and in hypoxia.

Cimmino F, Avitabile M, Lasorsa VA, Montella A, Pezone L, Cantalupo S, Visconte F, Corrias MV, Iolascon A, Capasso M.

BMC Med Genet. 2019 Feb 26;20(1):37. doi: 10.1186/s12881-019-0767-1.

4.

Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma.

Morandi F, Amoroso L, Dondero A, Castriconi R, Parodi S, Luksch R, Casale F, Castellano A, Garaventa A, Moretta A, Bottino C, Ponzoni M, Corrias MV.

Oncoimmunology. 2018 Jul 30;7(9):e1468953. doi: 10.1080/2162402X.2018.1468953. eCollection 2018.

PMID:
30357053
5.

miRNA expression profile of bone marrow resident cells from children with neuroblastoma is not significantly different from that of healthy children.

Stigliani S, Morandi F, Persico L, Lagazio C, Erminio G, Scaruffi P, Corrias MV.

Oncotarget. 2018 Apr 10;9(27):19014-19025. doi: 10.18632/oncotarget.24874. eCollection 2018 Apr 10.

6.

Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis.

Corrias MV, Parodi S, Tchirkov A, Lammens T, Vicha A, Pasqualini C, Träger C, Yáñez Y, Dallorso S, Varesio L, Luksch R, Laureys G, Valteau-Couanet D, Canete A, Pöetschger U, Ladenstein R, Burchill SA.

Pediatr Blood Cancer. 2018 Jul;65(7):e27052. doi: 10.1002/pbc.27052. Epub 2018 Mar 30.

7.

Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma.

Rigo V, Emionite L, Daga A, Astigiano S, Corrias MV, Quintarelli C, Locatelli F, Ferrini S, Croce M.

Sci Rep. 2017 Oct 25;7(1):14049. doi: 10.1038/s41598-017-14417-6.

8.

Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma.

Morandi F, Barco S, Stigliani S, Croce M, Persico L, Lagazio C, Scuderi F, Belli ML, Montera M, Cangemi G, Pozzi S, Rigo V, Scaruffi P, Amoroso L, Erminio G, Pistoia V, Ferrini S, Corrias MV.

Oncotarget. 2017 May 30;8(32):53194-53209. doi: 10.18632/oncotarget.18285. eCollection 2017 Aug 8.

9.

Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages.

Bellora F, Dondero A, Corrias MV, Casu B, Regis S, Caliendo F, Moretta A, Cazzola M, Elena C, Vinti L, Locatelli F, Bottino C, Castriconi R.

J Immunol. 2017 Aug 15;199(4):1516-1525. doi: 10.4049/jimmunol.1601695. Epub 2017 Jul 12.

10.

CD4+CD25hiCD127- Treg and CD4+CD45R0+CD49b+LAG3+ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma.

Morandi F, Pozzi S, Barco S, Cangemi G, Amoroso L, Carlini B, Pistoia V, Corrias MV.

Oncoimmunology. 2016 Oct 24;5(12):e1249553. doi: 10.1080/2162402X.2016.1249553. eCollection 2016.

11.

Soluble HLA-G and HLA-E Levels in Bone Marrow Plasma Samples Are Related to Disease Stage in Neuroblastoma Patients.

Morandi F, Pozzi S, Carlini B, Amoroso L, Pistoia V, Corrias MV.

J Immunol Res. 2016;2016:7465741. doi: 10.1155/2016/7465741. Epub 2016 Aug 16.

12.

PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance.

Dondero A, Pastorino F, Della Chiesa M, Corrias MV, Morandi F, Pistoia V, Olive D, Bellora F, Locatelli F, Castellano A, Moretta L, Moretta A, Bottino C, Castriconi R.

Oncoimmunology. 2015 Jul 15;5(1):e1064578. eCollection 2016.

13.

Expression of FOXP3, CD14, and ARG1 in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival.

Stigliani S, Croce M, Morandi F, Scaruffi P, Rigo V, Carlini B, Manzitti C, Gigliotti AR, Tonini GP, Pistoia V, Ferrini S, Corrias MV.

Biomed Res Int. 2015;2015:347867. doi: 10.1155/2015/347867. Epub 2015 Jun 16.

14.

Deregulation of focal adhesion pathway mediated by miR-659-3p is implicated in bone marrow infiltration of stage M neuroblastoma patients.

Stigliani S, Scaruffi P, Lagazio C, Persico L, Carlini B, Varesio L, Morandi F, Morini M, Gigliotti AR, Esposito MR, Viscardi E, Cecinati V, Conte M, Corrias MV.

Oncotarget. 2015 May 30;6(15):13295-308.

15.

IL-10 and ARG-1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome.

Morandi F, Croce M, Cangemi G, Barco S, Rigo V, Carlini B, Amoroso L, Pistoia V, Ferrini S, Corrias MV.

J Immunol Res. 2015;2015:718975. doi: 10.1155/2015/718975. Epub 2015 Apr 19.

16.

New immunotherapeutic strategies for the treatment of neuroblastoma.

Croce M, Corrias MV, Rigo V, Ferrini S.

Immunotherapy. 2015;7(3):285-300. doi: 10.2217/imt.14.117. Review.

PMID:
25804480
17.

Evaluation of bone marrow as a metastatic site of human neuroblastoma.

Morandi F, Corrias MV, Pistoia V.

Ann N Y Acad Sci. 2015 Jan;1335:23-31. doi: 10.1111/nyas.12554. Epub 2014 Oct 14. Review.

PMID:
25315505
18.

The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma.

Ferretti E, Tripodo C, Pagnan G, Guarnotta C, Marimpietri D, Corrias MV, Ribatti D, Zupo S, Fraternali-Orcioni G, Ravetti JL, Pistoia V, Corcione A.

Leukemia. 2015 Apr;29(4):958-67. doi: 10.1038/leu.2014.291. Epub 2014 Oct 6.

PMID:
25283844
19.

Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity.

Rigo V, Corrias MV, Orengo AM, Brizzolara A, Emionite L, Fenoglio D, Filaci G, Croce M, Ferrini S.

Cancer Immunol Immunother. 2014 May;63(5):501-11. doi: 10.1007/s00262-014-1536-9. Epub 2014 Mar 20.

PMID:
24647609
20.

Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.

Viprey VF, Gregory WM, Corrias MV, Tchirkov A, Swerts K, Vicha A, Dallorso S, Brock P, Luksch R, Valteau-Couanet D, Papadakis V, Laureys G, Pearson AD, Ladenstein R, Burchill SA.

J Clin Oncol. 2014 Apr 1;32(10):1074-83. doi: 10.1200/JCO.2013.53.3604. Epub 2014 Mar 3.

PMID:
24590653
21.

Plasma levels of soluble HLA-E and HLA-F at diagnosis may predict overall survival of neuroblastoma patients.

Morandi F, Cangemi G, Barco S, Amoroso L, Giuliano M, Gigliotti AR, Pistoia V, Corrias MV.

Biomed Res Int. 2013;2013:956878. doi: 10.1155/2013/956878. Epub 2013 Nov 21.

22.

Seasonal variations of date of diagnosis and birth for neuroblastoma patients in Italy.

Parodi S, Fontana V, Haupt R, Corrias MV.

Cancer Epidemiol. 2013 Oct;37(5):575-8. doi: 10.1016/j.canep.2013.07.003. Epub 2013 Aug 8.

PMID:
23932492
23.

Neuroblastoma-derived TGF-β1 modulates the chemokine receptor repertoire of human resting NK cells.

Castriconi R, Dondero A, Bellora F, Moretta L, Castellano A, Locatelli F, Corrias MV, Moretta A, Bottino C.

J Immunol. 2013 May 15;190(10):5321-8. doi: 10.4049/jimmunol.1202693. Epub 2013 Apr 10.

24.

Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma.

Calafiore L, Amoroso L, Della Casa Alberighi O, Luksch R, Zanazzo G, Castellano A, Podda M, Dominici C, Haupt R, Corrias MV, Garaventa A.

Ann Oncol. 2013 May;24(5):1406-13. doi: 10.1093/annonc/mds648. Epub 2013 Feb 7.

PMID:
23396605
25.

Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma.

Cangemi G, Reggiardo G, Barco S, Barbagallo L, Conte M, D'Angelo P, Bianchi M, Favre C, Galleni B, Melioli G, Haupt R, Garaventa A, Corrias MV.

Onco Targets Ther. 2012;5:417-23. doi: 10.2147/OTT.S36366. Epub 2012 Nov 30.

26.

Restricted ROC curves are useful tools to evaluate the performance of tumour markers.

Parodi S, Muselli M, Carlini B, Fontana V, Haupt R, Pistoia V, Corrias MV.

Stat Methods Med Res. 2016 Feb;25(1):294-314. doi: 10.1177/0962280212452199. Epub 2012 Jun 26.

PMID:
22735161
27.

Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-G proteins.

Morandi F, Scaruffi P, Gallo F, Stigliani S, Moretti S, Bonassi S, Gambini C, Mazzocco K, Fardin P, Haupt R, Arcamone G; Italian Cooperative Group for Neuroblastoma, Pistoia V, Tonini GP, Corrias MV.

PLoS One. 2012;7(1):e29922. doi: 10.1371/journal.pone.0029922. Epub 2012 Jan 9.

28.

Identification of reference microRNAs and suitability of archived hemopoietic samples for robust microRNA expression profiling.

Viprey VF, Corrias MV, Burchill SA.

Anal Biochem. 2012 Feb 15;421(2):566-72. doi: 10.1016/j.ab.2011.10.022. Epub 2011 Oct 18.

PMID:
22074795
29.

Bone marrow of neuroblastoma patients shows downregulation of CXCL12 expression and presence of IFN signature.

Scaruffi P, Morandi F, Gallo F, Stigliani S, Parodi S, Moretti S, Bonassi S, Fardin P, Garaventa A, Zanazzo G, Pistoia V, Tonini GP, Corrias MV.

Pediatr Blood Cancer. 2012 Jul 15;59(1):44-51. doi: 10.1002/pbc.23339. Epub 2011 Oct 12.

PMID:
21994039
30.

Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients.

Morandi F, Corrias MV, Levreri I, Scaruffi P, Raffaghello L, Carlini B, Bocca P, Prigione I, Stigliani S, Amoroso L, Ferrone S, Pistoia V.

Cancer Immunol Immunother. 2011 Oct;60(10):1485-95. doi: 10.1007/s00262-011-1052-0. Epub 2011 Jun 10.

31.

Why do cancer omics attract clinicians so much?

Massimo L, Corrias MV, Tonini GP.

OMICS. 2011 Mar;15(3):123-4. doi: 10.1089/omi.2010.0081. No abstract available.

PMID:
21375460
32.

Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors.

Corrias MV, Haupt R, Carlini B, Cappelli E, Giardino S, Tripodi G, Tonini GP, Garaventa A, Pistoia V, Pistorio A.

Pediatr Blood Cancer. 2012 Jan;58(1):43-9. doi: 10.1002/pbc.22960. Epub 2011 Jan 19.

PMID:
21254375
33.

Neuroblastoma and bone metastases: clinical significance and prognostic value of Dickkopf 1 plasma levels.

Granchi D, Corrias MV, Garaventa A, Baglìo SR, Cangemi G, Carlini B, Paolucci P, Giunti A, Baldini N.

Bone. 2011 Jan;48(1):152-9. doi: 10.1016/j.bone.2010.06.028. Epub 2010 Jul 14.

PMID:
20603237
34.

Detection of cell-free RNA in children with neuroblastoma and comparison with that of whole blood cell RNA.

Corrias MV, Pistorio A, Cangemi G, Tripodi G, Carlini B, Scaruffi P, Fardin P, Garaventa A, Pistoia V, Haupt R.

Pediatr Blood Cancer. 2010 Jul 1;54(7):897-903. doi: 10.1002/pbc.22498.

PMID:
20405510
35.

Different subcellular localization of ALCAM molecules in neuroblastoma: Association with relapse.

Corrias MV, Gambini C, Gregorio A, Croce M, Barisione G, Cossu C, Rossello A, Ferrini S, Fabbi M.

Cell Oncol. 2010;32(1-2):77-86. doi: 10.3233/CLO-2009-0494.

36.

Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice.

Croce M, Corrias MV, Orengo AM, Brizzolara A, Carlini B, Borghi M, Rigo V, Pistoia V, Ferrini S.

Int J Cancer. 2010 Sep 1;127(5):1141-50. doi: 10.1002/ijc.25140.

37.

Umbilical cord blood transplantation: should perinatal solid cancer become a matter of concern?

Corrias MV, Dallorso S, Haupt R, Martini I, Morandi F, Carlini B, Pistoia V, Garaventa A.

J Natl Cancer Inst. 2008 Dec 17;100(24):1822-3. doi: 10.1093/jnci/djn405. Epub 2008 Dec 9. No abstract available.

PMID:
19066266
38.

Chemokines in neuroectodermal tumour progression and metastasis.

Raffaghello L, Cocco C, Corrias MV, Airoldi I, Pistoia V.

Semin Cancer Biol. 2009 Apr;19(2):97-102. doi: 10.1016/j.semcancer.2008.10.003. Epub 2008 Nov 1. Review.

PMID:
19013246
39.

Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials.

Viprey VF, Lastowska MA, Corrias MV, Swerts K, Jackson MS, Burchill SA.

J Pathol. 2008 Oct;216(2):245-52. doi: 10.1002/path.2406.

PMID:
18702176
40.

Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule.

Gregorio A, Corrias MV, Castriconi R, Dondero A, Mosconi M, Gambini C, Moretta A, Moretta L, Bottino C.

Histopathology. 2008 Jul;53(1):73-80. doi: 10.1111/j.1365-2559.2008.03070.x.

41.

Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen.

Croce M, Meazza R, Orengo AM, Fabbi M, Borghi M, Ribatti D, Nico B, Carlini B, Pistoia V, Corrias MV, Ferrini S.

Cancer Immunol Immunother. 2008 Nov;57(11):1625-34. doi: 10.1007/s00262-008-0496-3. Epub 2008 Mar 7.

PMID:
18324400
42.

Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma.

Corrias MV, Parodi S, Haupt R, Lacitignola L, Negri F, Sementa AR, Dau D, Scuderi F, Carlini B, Bianchi M, Casale F, Faulkner L, Garaventa A.

Br J Cancer. 2008 Jan 29;98(2):263-9. doi: 10.1038/sj.bjc.6604179. Epub 2008 Jan 8.

43.

Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice.

Castriconi R, Dondero A, Cilli M, Ognio E, Pezzolo A, De Giovanni B, Gambini C, Pistoia V, Moretta L, Moretta A, Corrias MV.

Cancer Immunol Immunother. 2007 Nov;56(11):1733-42. Epub 2007 Apr 11.

PMID:
17426969
44.

Tumor origin of endothelial cells in human neuroblastoma.

Pezzolo A, Parodi F, Corrias MV, Cinti R, Gambini C, Pistoia V.

J Clin Oncol. 2007 Feb 1;25(4):376-83.

PMID:
17264333
45.

Diagnostic identification of malignant cells in the cerebrospinal fluid by tumor-specific qRT-PCR.

Rosanda C, Gambini C, Carlini B, Conte M, De Bernardi B, Garaventa A, Corrias MV.

Clin Exp Metastasis. 2006;23(3-4):223-6. Epub 2006 Sep 22.

PMID:
17028920
46.

Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET.

Viprey VF, Corrias MV, Kagedal B, Oltra S, Swerts K, Vicha A, Ladenstein R, Burchill SA.

Eur J Cancer. 2007 Jan;43(2):341-50. Epub 2006 Oct 4.

PMID:
17023157
47.

Peripheral blood stem cell tumor cell contamination and survival of neuroblastoma patients.

Corrias MV, Haupt R, Carlini B, Parodi S, Rivabella L, Garaventa A, Pistoia V, Dallorso S.

Clin Cancer Res. 2006 Oct 1;12(19):5680-5.

48.

Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.

Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias MV, Pistoia V, Ribatti D, Pagnan G, Ponzoni M.

J Natl Cancer Inst. 2006 Aug 16;98(16):1142-57.

PMID:
16912267
49.

Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon-gamma.

Ribatti D, Nico B, Pezzolo A, Vacca A, Meazza R, Cinti R, Carlini B, Parodi F, Pistoia V, Corrias MV.

Br J Cancer. 2006 Jun 19;94(12):1845-52. Epub 2006 May 23.

50.

CXCL12 does not attract CXCR4+ human metastatic neuroblastoma cells: clinical implications.

Airoldi I, Raffaghello L, Piovan E, Cocco C, Carlini B, Amadori A, Corrias MV, Pistoia V.

Clin Cancer Res. 2006 Jan 1;12(1):77-82.

Supplemental Content

Loading ...
Support Center